



PROVIDENCE
HOSPITAL

DOCKET NUMBER
PETITION RULE PRM 35-9
(54FR38239)

405

DOCKETED
USNRC

'89 DEC 13 P4:17

December 11, 1989

OFFICE OF SECRETARY
DOCKETING & SERVICE
BRANCH

Secretary of the Commission
U.S. Nuclear Regulatory Commission
Docketing and Service Branch, Docket #PRM-35-9
Washington, D.C. 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing (Nuclear Medicine physician, at Providence Hospital 1150 Varnum Street, N.E., Washington, D.C. 20017. I am deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material as they significantly impact my ability to practice high-quality Nuclear Medicine/Nuclear Pharmacy and are preventing me from providing optimised care to individual patients.

For example, because radiopharmaceutical companies prefer not to help community hospitals like ours to obtain IND's, we cannot use new agents on our patient until years after they have been available to large centers which have no difficulty in obtaining IND's. This places our patients in a second class citizen's category, and deprives many from earlier diagnoses. It also adds to the eventual cost of isotopes making them less cost-effective when generally available. This is particularly so when large centers do not pay for the isotopes they use during clinical trials; the smaller hospitals like ours end up sharing this expense through higher costs of isotopes which in turn make procedures more costly to the patients, our consumers and our common public.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that described new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapeutic procedures. In many cases, manufactures will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35,300 and 33.17 (a)(4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

8912210286 891211
PDR PRM
35-9 PDR


PS10

Finally, I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal, studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission on Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and prepare these materials.

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety, I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,

A handwritten signature in cursive script, appearing to read "Carlos R. Matta". The signature is written in dark ink and is positioned above the typed name and title.

Carlos R. Matta
Chief, Nuclear Medicine